A detailed history of Pro Share Advisors LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 13,421 shares of ALT stock, worth $110,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,421
Holding current value
$110,723
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.5 - $8.1 $73,815 - $108,710
13,421 New
13,421 $82,000
Q2 2022

Aug 01, 2022

SELL
$3.94 - $11.77 $45,901 - $137,120
-11,650 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$5.9 - $9.45 $21,399 - $34,275
-3,627 Reduced 23.74%
11,650 $71,000
Q4 2021

Feb 08, 2022

BUY
$8.69 - $12.48 $14,894 - $21,390
1,714 Added 12.64%
15,277 $139,000
Q3 2021

Nov 12, 2021

SELL
$8.43 - $16.81 $14,811 - $29,535
-1,757 Reduced 11.47%
13,563 $153,000
Q2 2021

Aug 13, 2021

BUY
$9.85 - $16.46 $150,902 - $252,167
15,320 New
15,320 $151,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.